Achondroplasia

Overview and Genetics

Achondroplasia is the most common skeletal dysplasia and the most common cause of disproportionate short stature (dwarfism), affecting approximately 1 in 15,000–25,000 live births worldwide. Despite this wide phenotypic reach, its genetic basis is extraordinarily uniform: more than 99% of all achondroplasia cases result from one of two nucleotide changes at exactly the same codon in the FGFR3 gene — c.1138G>A (the more common change, accounting for approximately 98% of cases) or c.1138G>C (approximately 2%) — both producing the identical amino acid substitution p.Gly380Arg in fibroblast growth factor receptor 3. This protein is encoded on chromosome 4p16.3. The mutational specificity is striking and biologically meaningful: it reflects the gain-of-function nature of the defect. Unlike disorders driven by loss-of-function mutations — where many different DNA changes can disrupt a gene's function — achondroplasia requires a very specific structural change at this transmembrane-domain residue to lock the receptor into constitutive activation.

FGFR3 is a negative regulator of bone growth under normal circumstances. In cartilaginous growth plates, fibroblast growth factors bind FGFR3, activating it transiently to signal through the STAT1 and MAPK/ERK pathways. This signaling limits chondrocyte proliferation, columnar organization, and hypertrophic differentiation — coordinating the pace of skeletal growth with overall development. The p.Gly380Arg substitution destabilizes the transmembrane helix geometry, locking FGFR3 into a constitutively active (always-on) state even without FGF ligand present. The result is relentless suppression of chondrocyte activity throughout every long-bone growth plate, producing impaired endochondral ossification and the characteristic short-limb phenotype.

Approximately 80% of achondroplasia cases are de novo mutations — that is, they arise spontaneously in the egg or, far more commonly, the sperm — in individuals with no family history. The overwhelming majority of de novo mutations originate in paternal spermatogenesis, not maternal oogenesis. The reason relates to biology: men undergo continuous spermatogenesis throughout adult life, with spermatogonial stem cells dividing hundreds to thousands of times over decades. Each division carries a small risk of replication error, and the specific c.1138G>A transversion at the p.Gly380Arg codon appears to be a mutation-prone "hotspot" — possibly related to the local CpG dinucleotide context at this site, which is prone to spontaneous deamination of 5-methylcytosine. The paternal age effect is well-established: fathers aged 35 years or older have a measurably higher likelihood of fathering a child with de novo achondroplasia compared to younger fathers. The absolute risk remains small (achondroplasia is still rare), but the relative increase is real and has been documented in multiple large epidemiological studies.

The 20% of cases in which a parent is affected follow autosomal dominant inheritance: one copy of the p.Gly380Arg allele is sufficient to cause the full phenotype, and an affected individual has a 50% chance of passing it to each child. Homozygous achondroplasia — inheriting two copies of the p.Gly380Arg mutation — occurs when two people with achondroplasia have children together. Homozygotes have a far more severe skeletal phenotype with a narrow, bell-shaped thorax that is incompatible with effective breathing; the condition is perinatally lethal due to respiratory failure in the neonatal period or early infancy. This lethality in homozygotes, combined with reduced reproductive fitness of individuals with achondroplasia historically, means that the majority of new cases continue to arise through de novo mutation in each generation rather than through inheritance.

Back to Table of Contents

Clinical Features — Morphology and Growth

The defining hallmark of achondroplasia is rhizomelic short stature: the proximal limb segments — the humerus (upper arm) and the femur (thigh) — are disproportionately shortened relative to the middle segments (forearm, lower leg) and the trunk. "Rhizomelic" comes from the Greek for "root" — referring to the limb roots. Adult height averages approximately 131 cm (4 feet 3 inches) in men and 124 cm (4 feet 1 inch) in women, though there is variation around these means. Critically, intelligence is entirely normal. People with achondroplasia have the same cognitive capacity as the general population and full potential for academic achievement, professional careers, and rich social lives.

Macrocephaly with frontal bossing is universally present. The skull grows relatively normally in overall size — reflecting normal brain development — while the cranial base, which develops through endochondral ossification like the long bones, is shorter than normal. This mismatch produces an increased head circumference by standard percentile charts, a prominent protruding forehead (frontal bossing), and a flattened nasal bridge. The midfacial bones (maxilla, nasal bones) are hypoplastic, producing the characteristic appearance: the midface is relatively small and flat while the forehead and calvarium are normal or even enlarged in appearance.

Trident hand configuration is a classic feature visible at birth: the fingers are shortened and relatively equal in length, with a characteristic gap between the third and fourth digits so that when the hand is extended and the fingers are relaxed, three prongs appear — two pairs (index+middle and ring+little) plus the thumb, with the central gap giving the trident shape. The hands appear broad and short-fingered. Motor milestones in infancy and early childhood are delayed compared to population norms — not because of intellectual impairment, but because hypotonia (low muscle tone, common in infants with achondroplasia), rhizomelic limb shortening, and the proportionally large head make crawling, sitting, and walking mechanically more challenging. Most children with achondroplasia walk independently by 18–24 months (somewhat later than the 12-month average). Walking delays beyond 24–30 months warrant investigation for foramen magnum or spinal cord involvement.

Lumbar hyperlordosis — an exaggerated inward curvature of the lower back — is universally present in adults and develops after a child begins walking. It arises because the pelvis is tilted forward and the posterior iliac wings are broad, creating a characteristic posture with the abdomen and buttocks protruding. This same lumbar anatomy contributes directly to adult spinal stenosis. Genu varum (bow-leggedness) is common in childhood and may progress to significant angular deformity requiring orthopedic assessment. Femoral internal rotation and hypermobile joints contribute to the typical stance and gait pattern. Standard population growth charts do not apply; achondroplasia-specific growth charts (published by Horton, Rotter, Rimoin and colleagues and periodically updated) should be used to track growth velocity and assess whether a child is growing along their own curve — growth deceleration within achondroplasia standards can signal a treatable intercurrent problem.

The chest in infants with achondroplasia may be narrow — a narrowed anteroposterior thoracic diameter and relatively short ribs — which reduces pulmonary reserve and contributes to respiratory vulnerability in the newborn period and infancy. Adults typically have a normal or near-normal chest configuration. The trunk length is relatively preserved compared to limb length, so sitting height is less affected than standing height.

Back to Table of Contents

Foramen Magnum Stenosis — The Most Critical Medical Concern in Infancy

The foramen magnum is the opening at the base of the skull through which the brainstem exits the cranial cavity and continues as the cervical spinal cord. In achondroplasia, the skull base — which develops through endochondral ossification — is hypoplastic, producing a foramen magnum that is substantially smaller than normal. This narrowing creates a critical bottleneck around the brainstem and upper cervical spinal cord, with potential consequences ranging from subtle neurological signs to sudden death. Foramen magnum stenosis is the most life-threatening complication of achondroplasia in the first few years of life and is the primary driver of what was historically a higher rate of sudden unexplained infant death in achondroplasia compared to the general population.

Compression of the cervicomedullary junction — the region where the lower brainstem (medulla oblongata) meets the upper cervical spinal cord — can produce multiple problems. Central sleep apnea occurs when the respiratory control centers in the medulla are compressed, disrupting automatic breathing during sleep; this is distinctly different from obstructive sleep apnea (which is also common in achondroplasia) in that the brain simply fails to send the breathing signal. Hypotonia — low muscle tone affecting head control and motor development — is among the most common findings in infants with achondroplasia and frequently reflects cervicomedullary compression affecting descending motor tracts. Cervical myelopathy can cause progressive motor dysfunction, hyperreflexia, clonus (rhythmic involuntary muscle contractions), and in severe cases, spastic quadriparesis. Sudden infant death is the most feared outcome, believed to result from acute brainstem compression causing apnea or cardiovascular instability — typically occurring during sleep.

Risk is concentrated in the first two years of life and is highest between 6 months and 24 months. Systematic surveillance is therefore mandatory for all infants diagnosed with achondroplasia. The recommended protocol includes: MRI of the cervicomedullary junction at diagnosis (to characterize the foramen magnum dimensions, assess for evidence of cord signal change, and look for coning or compression); polysomnography (sleep study) to detect and quantify central apnea episodes; and careful serial neurological examination at every health supervision visit assessing deep tendon reflexes, clonus, muscle tone, and motor milestone progress. Foramen magnum area below 4 standard deviations for age, the presence of myelopathic signs, documented central apnea, progressive hypotonia, or imaging evidence of cord compression are indications for neurosurgical consultation.

Surgical treatment — posterior fossa craniectomy with C1-C2 laminectomy (foramen magnum decompression) — is effective and, when performed before irreversible cord injury occurs, is associated with normalization of neurological function, resolution of central apnea, and a dramatic reduction in sudden death risk. The timing of intervention requires multidisciplinary judgment: neurosurgery, neurology, sleep medicine, and genetics working together in a center experienced in achondroplasia management. The surgery carries real procedural risks in very young infants, which must be weighed against the serious consequences of untreated stenosis. Most experienced centers recommend a relatively low threshold for surgery in symptomatic infants given the favorable risk-benefit profile of decompression versus the catastrophic potential of untreated compression.

Back to Table of Contents

Respiratory and Sleep Complications

Obstructive sleep apnea (OSA) is extraordinarily prevalent in achondroplasia across all age groups, affecting 30–80% of children in some published series and remaining highly prevalent in adults. The structural causes are multiple and overlapping. Midface hypoplasia narrows the entire upper airway from the nasopharynx through the oropharynx: the choanal dimensions are reduced, the nasal passages are narrower, and the airway behind the soft palate is tighter. Tonsillar and adenoidal tissue, which is of normal absolute size, is disproportionately large relative to the smaller upper airway space — a double burden. The tongue and soft palate are also relatively large for the oral cavity. Together, these structural features produce a chronically narrowed upper airway that collapses readily during sleep when pharyngeal muscle tone is relaxed.

Symptoms of OSA include loud snoring (nearly universal in achondroplasia), witnessed apneic pauses during sleep, restless and non-restorative sleep, morning headaches from overnight hypercapnia, excessive daytime sleepiness, behavioral disturbances (hyperactivity, inattention, irritability in children — frequently misattributed to behavioral disorders), and, in severe chronic cases, impaired growth (because growth hormone secretion is pulsatile during sleep and severe OSA disrupts these pulses). Universal sleep study (polysomnography) by age 2–3 years is recommended for all children with achondroplasia, with repeat testing as symptoms change or as an annual or biennial surveillance tool, since the severity of OSA fluctuates with adenoidal growth, weight, and structural changes over development.

Adenotonsillectomy is the first-line treatment for pediatric OSA in achondroplasia and is highly effective in appropriately selected patients — adenoidal and tonsillar hypertrophy are so common that surgical removal reliably enlarges the retropalatal and retroglossal airspace and reduces OSA severity. Many children do not achieve full resolution of OSA from surgery alone due to the underlying midface structural limitation, and postoperative sleep study is essential. Continuous positive airway pressure (CPAP) or bilevel PAP (BiPAP) is used when surgery is contraindicated, insufficient, or in adults. Fitting CPAP in young children requires specialized pediatric sleep medicine experience. In severe anatomical cases that do not respond to adenotonsillectomy and PAP therapy, additional surgical options include: mandibular distraction osteogenesis, maxillofacial skeletal surgery to advance the midface, or rarely tracheostomy. Untreated severe OSA in achondroplasia leads to pulmonary hypertension from chronic intermittent hypoxemia, right ventricular strain, impaired neurocognitive development, and poor growth.

Respiratory risks during anesthesia deserve specific attention. Midface hypoplasia, macrocephaly with relative occipital prominence (which causes neck flexion when the patient is supine without head-positioning aids), and the narrow upper airway make intubation more challenging than in the general population. Anesthesiologists managing patients with achondroplasia must be briefed on these anatomical factors in advance; appropriate positioning aids (shoulder rolls to maintain cervical extension), video-laryngoscopy availability, and experienced personnel are essential for safe airway management. The restrictive respiratory physiology from a narrow rib cage reduces pulmonary reserve and demands careful attention to respiratory status perioperatively.

Back to Table of Contents

Spinal Complications

Spinal complications are the dominant source of morbidity in adult patients with achondroplasia and the leading cause of adult disability in this population. The spine is affected at multiple levels and by multiple mechanisms, with consequences that unfold progressively from childhood through middle age.

Lumbar spinal stenosis is nearly universal in adults and typically produces symptomatic neurological compromise by the third to fifth decade of life. The anatomical basis is an unhappy convergence of achondroplasia-specific vertebral abnormalities: short pedicles (dramatically reducing the anteroposterior depth of the spinal canal), narrowed interpedicular distance (reducing the lateral width of the canal), vertebral body wedging, and progressive lumbar lordosis that causes the facet joints and ligamenta flava to buckle inward. The combined effect is a lumbar spinal canal that may be only one-third to one-half the normal cross-sectional area. As adults age and develop additional spondylotic changes — disc degeneration, facet joint hypertrophy, osteophyte formation — the residual canal space is further compromised.

The clinical syndrome is neurogenic claudication: aching, cramping leg pain, numbness, tingling, and/or weakness that comes on predictably after walking a certain distance and is dramatically relieved by sitting or by bending forward (spinal flexion opens the canal slightly). The classic behavioral adaptation — walking while bent forward pushing a shopping cart — is so characteristic that it has a name: the "shopping cart sign" or "stooped gait." MRI confirms the diagnosis by demonstrating multilevel lumbar stenosis. Neurological examination may reveal diminished reflexes, reduced lower extremity muscle strength, and altered sensation in a distribution matching the compressed nerve roots. Bladder dysfunction (neurogenic bladder) and bowel symptoms indicate severe cauda equina involvement and warrant urgent surgical referral.

Surgical treatment — lumbar decompressive laminectomy, typically spanning multiple levels — reliably improves neurogenic claudication and quality of life and is required in the majority of adults with achondroplasia at some point. The surgical goal is to enlarge the canal by removing the posterior bony arch (laminae) and the hypertrophied ligamenta flava. Because the canal is congenitally narrow, thorough and often multilevel decompression is necessary. Outcomes are generally excellent when surgery is performed before permanent nerve damage has occurred.

Thoracolumbar kyphosis (a posterior rounding or "gibbus" deformity at the thoracolumbar junction) is nearly universal in infancy and early childhood. Its cause is multifactorial: trunk hypotonia makes it difficult for infants to maintain an upright posture, and when placed in seated positions — in bouncers, infant carriers, or seated walkers — before they have sufficient truncal control, gravity drives exaggerated rounding at the thoracolumbar junction. Prolonged mechanical loading in this position promotes anterior wedging of the thoracolumbar vertebral bodies. Most kyphosis resolves spontaneously once a child achieves independent sitting and develops truncal muscle strength, typically by 18–24 months. Management of infantile kyphosis includes: avoiding devices that place unsupported infants in a flexed seated posture; encouraging prone ("tummy time") positioning to build extensor muscle strength; and monitoring the spine clinically and radiographically. Kyphosis that is severe (kyphotic angle >30 degrees), associated with vertebral body wedging on X-ray, or that fails to resolve by the time independent sitting is established requires more active management: physical therapy focused on back extensor strengthening, and in some cases a thoracolumbar orthosis (brace). Surgical correction is reserved for rigid, progressive kyphosis with vertebral wedging and neurological risk — spinal cord compression from severe kyphosis at the thoracolumbar junction is a real, if uncommon, complication. MRI evaluation is indicated for any child with kyphosis who shows neurological symptoms or signs.

Back to Table of Contents

ENT and Hearing — Recurrent Otitis Media and Cranial Nerve Features

Otitis media (middle ear infection) is the most frequent medical problem encountered in childhood achondroplasia, occurring in over 90% of children and recurring throughout childhood in most. The anatomical basis is well understood: midface hypoplasia produces shortened, horizontally oriented Eustachian tubes with abnormal cartilaginous support. The Eustachian tube normally serves to equalize pressure between the middle ear cavity and the nasopharynx and to drain secretions from the middle ear. In achondroplasia, impaired Eustachian tube function causes chronic negative middle ear pressure, persistent middle ear fluid (otitis media with effusion, commonly called "glue ear"), and susceptibility to acute bacterial superinfection of this stagnant fluid (acute otitis media).

The consequences of untreated, recurrent otitis media are significant: conductive hearing loss from fluid in the middle ear space (chronic effusion physically prevents normal eardrum vibration and ossicular chain movement), speech and language delay (a child who cannot hear normally during the critical window for language acquisition accumulates phonological and vocabulary deficits), and, with chronic infection, tympanic membrane perforation, chronic otorrhea, and scarring. Permanent conductive hearing loss from chronic middle ear disease is common in adults with achondroplasia who were inadequately managed in childhood.

Management requires a proactive and aggressive approach. At every well-child visit, hearing must be assessed and the tympanic membranes examined. Formal audiological testing (behavioral audiometry, tympanometry) is recommended starting in infancy and repeated at least annually. Acute otitis media is treated with antibiotics per current guidelines. When fluid persists bilaterally for three months or more, or when hearing loss is documented, tympanostomy tube placement (myringotomy tubes, "ear tubes") should be offered. Tube insertion is highly effective at draining effusion, ventilating the middle ear, and restoring hearing — and it is performed very frequently in achondroplasia, often multiple times in childhood as tubes are extruded and fluid recurs. Adenoidectomy is often combined with tube placement, as adenoidal hypertrophy contributes to Eustachian tube dysfunction. Speech and language therapy should be initiated promptly when delays are identified.

Sensorineural hearing loss — from inner ear or auditory nerve dysfunction rather than middle ear mechanics — also occurs in achondroplasia at an elevated rate compared to the general population and should be screened for with formal audiometry, as it requires different management (hearing aids, cochlear implants for severe cases) than conductive hearing loss. Dental and orthodontic problems are nearly universal: midfacial hypoplasia produces dental crowding, malocclusion, posterior crossbite, and Class III dental relationship (underbite appearance from relative mandibular prognathism). Orthodontic evaluation should begin by school age, and many patients require orthodontic and/or surgical-orthodontic treatment in adolescence and adulthood. Speech articulation difficulties reflecting both the dentofacial anatomy and relative macroglossia are common, and speech therapy evaluation is appropriate when articulation concerns are raised by parents or teachers.

Back to Table of Contents

Diagnosis — Prenatal and Postnatal

Achondroplasia can be diagnosed with high accuracy both before birth and at delivery, and the tools available for prenatal detection have expanded considerably in recent years.

Prenatal ultrasound is the traditional and still widely used approach. The characteristic short-limb phenotype typically becomes detectable on ultrasound between 20 and 24 weeks of gestation — sometimes earlier in experienced centers. Key ultrasound findings that raise suspicion for achondroplasia include: femur and humerus length Z-scores below −2 (short and bowed long bones) with a relative discrepancy compared to head circumference and abdominal circumference (which remain relatively normal, creating the characteristic disproportion); macrocephaly with frontal bossing detectable on head measurements; a narrow thoracic inlet in severe cases; polyhydramnios (excess amniotic fluid, reflecting reduced fetal swallowing efficiency); and a flat facial profile. Standard biometric dating formulas underestimate gestational age when applied to achondroplastic fetuses. Ultrasound findings in the second trimester should prompt detailed fetal survey at a maternal-fetal medicine or fetal imaging center with experience in skeletal dysplasias.

Cell-free fetal DNA (cfDNA / NIPT) testing from maternal plasma has transformed prenatal diagnosis for specific point mutations. Commercial panels from Illumina (UNITY screen) and other platforms now detect the c.1138G>A variant in fetal cfDNA with sensitivity exceeding 98% and high specificity. This allows non-invasive diagnosis from a maternal blood draw as early as 10–12 weeks of gestation — far earlier than ultrasound signs typically appear. NIPT is particularly valuable for couples with a family history of achondroplasia and for pregnancies where routine ultrasound raises concern. A positive cfDNA result should be confirmed with molecular diagnostic testing (chorionic villus sampling or amniocentesis plus targeted sequencing) before clinical decisions are made, but NIPT provides remarkably accurate early information.

Invasive prenatal diagnosis via chorionic villus sampling (CVS, performed at 10–12 weeks) or amniocentesis (performed at 15–20 weeks) combined with targeted analysis for the p.Gly380Arg mutation provides definitive prenatal diagnosis and is offered to couples with a family history of achondroplasia (50% recurrence risk if one parent is affected), to couples who have previously had a child with achondroplasia, or when ultrasound and/or cfDNA findings suggest the diagnosis.

Postnatal diagnosis at birth is typically straightforward. The combination of rhizomelic limb shortening, macrocephaly with frontal bossing, midface hypoplasia, and trident hands is visually characteristic and clinically recognizable to experienced neonatologists and clinical geneticists. Skeletal radiographic survey confirms diagnosis: characteristic squared iliac wings ("tombstone" pelvis), short and broad long bones with metaphyseal flaring, "champagne glass" pelvis, narrow intervertebral distances, and delayed ossification of femoral epiphyses are seen. Molecular genetic testing — sequencing of FGFR3 to confirm the p.Gly380Arg variant — is performed to confirm diagnosis, facilitate genetic counseling, and document genotype for future therapeutic eligibility (including vosoritide clinical trial enrollment and current label criteria).

The differential diagnosis of achondroplasia includes other skeletal dysplasias that produce rhizomelic limb shortening and similar clinical appearances. Hypochondroplasia is caused by different missense mutations in FGFR3 (most often p.Asn540Lys), produces a milder phenotype with less pronounced frontal bossing and macrocephaly, and may be misdiagnosed as familial short stature without molecular testing. Thanatophoric dysplasia (types I and II) results from other gain-of-function FGFR3 mutations with more potent receptor activation, is far more severe, and is lethal in the perinatal period due to extreme thoracic restriction and respiratory failure. Pseudoachondroplasia — caused by mutations in the COMP gene — resembles achondroplasia in producing rhizomelic short stature but is distinguished by normal birth length, normal facies, and onset of clinical features after age 2. Diastrophic dysplasia (SLC26A2 gene) produces severe short stature with club feet, "hitchhiker thumb," progressive joint contractures, and characteristic cauliflower-ear deformity.

Back to Table of Contents

Treatment — Growth Therapy and Medical Management

Vosoritide (Voxzogo; also known by the investigational name BMN 111; developed by BioMarin Pharmaceutical) received FDA approval in November 2021 and EMA approval in 2021, becoming the first pharmacological therapy that directly addresses the pathological mechanism of achondroplasia rather than merely managing its complications. Vosoritide is a C-type natriuretic peptide (CNP) analog, specifically a modified form of CNP that is resistant to enzymatic degradation. CNP acts on NPR-B (natriuretic peptide receptor B) in chondrocytes and activates a signaling cascade that counteracts the pathologically excessive FGFR3 activity driving achondroplasia — essentially pushing back against the overactive FGFR3 brake on bone growth and allowing chondrocytes to proliferate and differentiate more normally.

The pivotal Phase 3 clinical trial (Savarirayan et al., New England Journal of Medicine, 2020) enrolled 121 children aged 5–18 years with open growth plates and confirmed achondroplasia (p.Gly380Arg mutation). Vosoritide 15 mcg/kg/day subcutaneously versus placebo. The primary endpoint — annualized height velocity (AHV) — showed a clinically and statistically significant increase: 3.77 cm/year in the vosoritide group versus 2.20 cm/year in the placebo group, a difference of 1.57 cm/year (p<0.0001). Secondary endpoints including standing height Z-score, upper-to-lower body segment ratio, and head circumference Z-score also showed favorable trends. Adverse events were manageable: the most common was transient hypotension immediately post-injection (CNP has vasodilatory effects), which resolved without treatment in most cases; local injection site reactions were also common. Vosoritide is administered as a daily subcutaneous injection, typically self-administered or administered by a parent, after clinical training.

Long-term open-label extension studies are ongoing, tracking whether the height velocity benefit translates into meaningful gains in adult height and whether vosoritide influences other skeletal outcomes — including foramen magnum dimensions, spinal canal dimensions, and the frequency of surgical interventions. The FDA-approved indication is for children aged 5 years and older with open growth plates; studies in younger children and infants are underway. Vosoritide is approved only for the specific p.Gly380Arg mutation and requires molecular confirmation before prescribing.

Additional therapies under investigation include: infigratinib (a small molecule FGFR1-3 inhibitor taken orally), which directly blocks the constitutively active FGFR3 receptor; TransCon CNP (a long-acting CNP analog from Ascendis Pharma, designed for weekly rather than daily injection, currently in Phase 3 trials); and recifercept (a soluble FGFR3 decoy receptor from Pfizer that competitively sequesters FGF ligands away from the gain-of-function receptor). Each approach targets the same pathological pathway from a different angle, and it is likely that multiple approved options will be available in the coming years, expanding access and offering choice.

Growth hormone therapy has been used off-label for years in achondroplasia and can produce a modest increase in growth velocity in the first 1–2 years of treatment. However, the effect diminishes over time, and evidence that growth hormone significantly changes adult height in achondroplasia is limited; it is not recommended as a standard treatment and has largely been supplanted by vosoritide in centers where the newer drug is available and covered.

Limb-lengthening surgery using the Ilizarov external fixator technique or modern motorized intramedullary nailing (PRECICE system) can add 15–30 cm of height through staged lengthening procedures applied to the femur, tibia, and in some cases the humerus. Each limb segment is lengthened at approximately 1 mm/day, with the bone regenerating to fill the distraction gap (distraction osteogenesis). The process requires months to years of treatment, carries significant risks including pin tract infection, nerve or vessel injury, joint contracture, incomplete consolidation, and hardware complications, and demands enormous commitment from patient and family. The procedure is technically feasible and can achieve impressive height gains, but it is deeply controversial within the achondroplasia and dwarfism community: many people with achondroplasia and disability rights advocates oppose limb lengthening as a medically unnecessary normalization procedure performed on a condition that does not impair cognitive function or shorten lifespan with proper medical care. The decision is intensely personal, should not be made in childhood, and must be supported by thorough psychological and social support. Some individuals pursue it in adulthood having made an autonomous informed choice; others reject it entirely and thrive. Medical providers should present information without advocacy for a particular choice.

Medical management priorities across the lifespan include: MRI cervicomedullary junction surveillance in all infants; polysomnography for OSA at age 2–3 years and as clinically indicated; audiological testing at every visit in childhood; aggressive otitis media management with low threshold for tympanostomy tubes; orthopedic monitoring for kyphosis (infantile), genu varum, and lumbar stenosis; neurosurgical referral for symptomatic foramen magnum stenosis; annual neurological examination in adults to detect early spinal stenosis; and ongoing genetic counseling for the patient and family regarding inheritance, recurrence risks, and reproductive options including preimplantation genetic diagnosis. Little People of America (LPA, lpaonline.org) is the primary patient advocacy organization in the United States, providing peer support, community resources, health guidance, and advocacy for people of short stature and their families.

Back to Table of Contents

Key Research Papers

  1. Shiang R, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78(2):335-342. PMID: 7913883
  2. Savarirayan R, et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019;381(1):25-35. PMID: 31269546
  3. Hoover-Fong J, et al. Achondroplasia: Evaluation and management throughout the lifespan. Genet Med. 2021;23(12):2237-2244. PMID: 34385710
  4. Trotter TL, Hall JG; American Academy of Pediatrics Committee on Genetics. Health supervision for children with achondroplasia. Pediatrics. 2005;116(3):771-783. PMID: 16140717
  5. Pauli RM, et al. Apnea and sudden unexpected death in infants with achondroplasia. J Pediatr. 1984;104(3):342-348. PMID: 6699395
  6. Hecht JT, et al. Computed tomography of the foramen magnum: achondroplasia and associated anomalies. Radiology. 1985;155(1):201-204. PMID: 3975400
  7. Bagley CA, et al. Cervicomedullary decompression for foramen magnum stenosis in achondroplasia. J Neurosurg. 2006;104(3 Suppl):166-172. PMID: 16572629
  8. Mackenzie WG, et al. Spinal cord compression in achondroplasia. J Bone Joint Surg Am. 1994;76(4):631-639. PMID: 8150823
  9. Ireland PJ, et al. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014;7:117-125. PMID: 25018651
  10. Ornitz DM, Legeai-Mallet L. Achondroplasia: Development, pathogenesis, and therapy. Dev Dyn. 2017;246(4):291-309. PMID: 27987249
  11. Wright MJ, Irving MD. Clinical management of achondroplasia. Arch Dis Child. 2012;97(2):129-134. PMID: 22117023
  12. Legare JM. Achondroplasia. In: Adam MP, et al., eds. GeneReviews [Internet]. Seattle: University of Washington; 1993-2023 [updated 2023]. Available at: NBK1152

PubMed searches for ongoing research:
Achondroplasia + vosoritide | Achondroplasia + FGFR3 + treatment | Achondroplasia + foramen magnum

Back to Table of Contents

Connections